Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 9006
- Registration Number
- NCT02270242
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes
- Conditions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
- Target Recruit Count
- 700
- Registration Number
- NCT02265068
- Locations
- 🇩🇪
Vivantes-Klinikum Neukölln, Berlin, Germany
🇩🇪Klinikum Hildesheim GmbH, Hildesheim, Germany
🇩🇪Klinikum-Wetzlar Braunsfeld, Wetzlar, Germany
Ticagrelor and Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Hotel Dieu de France Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02261922
- Locations
- 🇱🇧
Hotel Dieu de France Hospital, Achrafieh, Beirut, Lebanon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 600
- Registration Number
- NCT02233790
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 46
- Registration Number
- NCT02230527
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT02227368
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 326
- Registration Number
- NCT02224534
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, CHONRANAM-Do, Korea, Republic of
🇸🇬National University Heart Centre, Singapore, Singapore
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of
Antiplatelet Therapy After Cardiac Arrest
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 57
- Registration Number
- NCT02224274
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Yong Huo
- Target Recruit Count
- 70
- Registration Number
- NCT02219412
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 74
- Registration Number
- NCT02217878
- Locations
- 🇵🇱
Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz, Kujawsko-pomorskie, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.